KALA PHARMA. INC (KALA)
Company Profile
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
What Happened?
KALA went public with their stock in 2017, and the price went as high as $26.00. They have not made a profit yet, and are spending much of their Cash on R&D.
The stock recently made New Highs for 2020, so somebody is Buying. Closing above $9.25 on High Volume would be Bullish. The Relative Strength on the daily chart is now 99.
When to Buy?
Wait for Break Out above $9.25 on High Volume.
Objective
Above the Green Line is watching KALA for a long term investment. Mutual Funds paid $26.00 for KALA in 2017, and it is now on Sale. Target is $18.00, if it can Break Out above $9.25 and then $9.25 becomes Support.
Follow the Rules: Above the Green Line + Above 90 Relative Strength
